- Home
- ACRS vs KOD Comparison
ACRS vs KOD Comparison
Compare ACRS & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- KOD
- Stock Information
- Founded
- ACRS 2012
- KOD 2009
- Country
- ACRS United States
- KOD United States
- Employees
- ACRS N/A
- KOD N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACRS Health Care
- KOD Health Care
- Exchange
- ACRS Nasdaq
- KOD Nasdaq
- Market Cap
- ACRS 165.7M
- KOD 188.9M
- IPO Year
- ACRS 2015
- KOD 2018
- Fundamental
- Price
- ACRS $1.45
- KOD $3.62
- Analyst Decision
- ACRS Strong Buy
- KOD Hold
- Analyst Count
- ACRS 8
- KOD 3
- Target Price
- ACRS $9.71
- KOD $9.00
- AVG Volume (30 Days)
- ACRS 755.2K
- KOD 294.1K
- Earning Date
- ACRS 08-06-2025
- KOD 08-13-2025
- Dividend Yield
- ACRS N/A
- KOD N/A
- EPS Growth
- ACRS N/A
- KOD N/A
- EPS
- ACRS N/A
- KOD N/A
- Revenue
- ACRS $17,777,000.00
- KOD N/A
- Revenue This Year
- ACRS N/A
- KOD N/A
- Revenue Next Year
- ACRS $11.77
- KOD N/A
- P/E Ratio
- ACRS N/A
- KOD N/A
- Revenue Growth
- ACRS N/A
- KOD N/A
- 52 Week Low
- ACRS $1.05
- KOD $1.92
- 52 Week High
- ACRS $5.17
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- ACRS 51.96
- KOD 46.82
- Support Level
- ACRS $1.37
- KOD $3.52
- Resistance Level
- ACRS $1.59
- KOD $3.78
- Average True Range (ATR)
- ACRS 0.10
- KOD 0.35
- MACD
- ACRS -0.01
- KOD -0.05
- Stochastic Oscillator
- ACRS 28.57
- KOD 30.77
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.